Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma

Nik Sol*, Sjors G. J. G. in 't Veld, Adrienne Vancura, Maud Tjerkstra, Cyra Leurs, Francois Rustenburg, Pepijn Schellen, Heleen Verschueren, Edward Post, Kenn Zwaan, Jip Ramaker, Laurine E. Wedekind, Jihane Tannous, Bauke Ylstra, Joep Killestein, Farrah Mateen, Sander Idema, Philip C. de Witt Hamer, Anna C. Navis, William P. J. LeendersAnn Hoeben, Bastiaan Moraal, David P. Noske, W. Peter Vandertop, R. Jonas A. Nilsson, Bakhos A. Tannous, Pieter Wesseling, Jaap C. Reijneveld, Myron G. Best, Thomas Wurdinger*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Tumor-educated platelets (TEPs) are potential biomarkers for cancer diagnostics. We employ TEP-derived RNA panels, determined by swarm intelligence, to detect and monitor glioblastoma. We assessed specificity by comparing the spliced RNA profile of TEPs from glioblastoma patients with multiple sclerosis and brain metastasis patients (validation series, n = 157; accuracy, 80%; AUC, 0.81 [95% CI, 0.74-0.89; p < 0.001]). Second, analysis of patients with glioblastoma versus asymptomatic healthy controls in an independent validation series (n = 347) provided a detection accuracy of 95% and AUC of 0.97 (95% CI, 0.95-0.99; p < 0.001). Finally, we developed the digitalSWARM algorithm to improve monitoring of glioblastoma progression and demonstrate that the TEP tumor scores of individual glioblastoma patients represent tumor behavior and could be used to distinguish false positive progression from true progression (validation series, n = 20; accuracy, 85%; AUC, 0.86 [95% CI, 0.70-1.00; p < 0.012]). In conclusion, TEPs have potential as a minimally invasive biosource for blood-based diagnostics and monitoring of glioblastoma patients.

Original languageEnglish
Article number100101
Number of pages13
JournalCell Reports Medicine
Volume1
Issue number7
DOIs
Publication statusPublished - 20 Oct 2020

Keywords

  • RESPONSE ASSESSMENT
  • MESSENGER-RNA
  • ADJUVANT TEMOZOLOMIDE
  • BLOOD-PLATELETS
  • EANO GUIDELINE
  • POOR SURVIVAL
  • CANCER
  • NEUROONCOLOGY
  • CELLS
  • LUNG

Cite this